London-based Neurofenix, a health tech startup, announced on Monday that it has secured $7M in a Series A round of funding led by AlbionVC.
HTH, InHealth Ventures, and existing investors also participated in the round.
The company says the capital will help it to accelerate product development and invest in US expansion, including funding US clinical trials.
Founded by Singla Buxarrais (CEO) and Dimitrios Athanasiou (CTO) in 2016, Neurofenix is a neurological rehabilitation platform that uses sensor technology to improve patient recovery outcomes.
Neurofenix’s rehab program currently focuses on arm and hand therapy through its NeuroBall device.
The company says the device was designed with input from over 300 therapists and patients.
The device is personalized to each patient based on their current needs and enables them to perform increasingly challenging, repetitive movements to help build up strength.
Read more on Tech Gist Africa:
UK-based BuiltAI raise £2 million
